Allianz Asset Management GmbH Makes New $4.30 Million Investment in ICU Medical, Inc. $ICUI

Allianz Asset Management GmbH bought a new position in shares of ICU Medical, Inc. (NASDAQ:ICUI) during the second quarter, HoldingsChannel.com reports. The firm bought 32,506 shares of the medical instruments supplier’s stock, valued at approximately $4,296,000.

Other hedge funds also recently added to or reduced their stakes in the company. GAMMA Investing LLC lifted its holdings in ICU Medical by 27.2% during the 1st quarter. GAMMA Investing LLC now owns 716 shares of the medical instruments supplier’s stock worth $99,000 after buying an additional 153 shares in the last quarter. Blue Trust Inc. lifted its holdings in ICU Medical by 23.0% during the 1st quarter. Blue Trust Inc. now owns 801 shares of the medical instruments supplier’s stock worth $111,000 after buying an additional 150 shares in the last quarter. United Services Automobile Association acquired a new stake in ICU Medical during the 1st quarter worth approximately $218,000. Johnson Investment Counsel Inc. lifted its holdings in ICU Medical by 17.7% during the 2nd quarter. Johnson Investment Counsel Inc. now owns 1,699 shares of the medical instruments supplier’s stock worth $225,000 after buying an additional 256 shares in the last quarter. Finally, Vontobel Holding Ltd. acquired a new stake in ICU Medical during the 1st quarter worth approximately $235,000. 96.10% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at ICU Medical

In related news, CEO Vivek Jain purchased 21,929 shares of the business’s stock in a transaction that occurred on Thursday, August 14th. The shares were purchased at an average cost of $112.84 per share, for a total transaction of $2,474,468.36. Following the purchase, the chief executive officer directly owned 130,149 shares of the company’s stock, valued at $14,686,013.16. The trade was a 20.26% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director David C. Greenberg purchased 1,200 shares of the business’s stock in a transaction that occurred on Wednesday, August 27th. The shares were bought at an average price of $126.42 per share, for a total transaction of $151,704.00. Following the completion of the purchase, the director directly owned 7,960 shares in the company, valued at $1,006,303.20. This represents a 17.75% increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.50% of the stock is owned by company insiders.

ICU Medical Price Performance

Shares of ICUI opened at $121.67 on Friday. ICU Medical, Inc. has a twelve month low of $107.00 and a twelve month high of $196.26. The firm’s fifty day simple moving average is $124.21 and its 200-day simple moving average is $129.51. The firm has a market capitalization of $3.00 billion, a price-to-earnings ratio of -80.05 and a beta of 0.83. The company has a current ratio of 2.44, a quick ratio of 1.17 and a debt-to-equity ratio of 0.63.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $2.10 EPS for the quarter, topping the consensus estimate of $1.44 by $0.66. ICU Medical had a negative net margin of 1.56% and a positive return on equity of 7.24%. The firm had revenue of $543.57 million for the quarter, compared to analyst estimates of $543.33 million. During the same period last year, the business earned $1.56 EPS. ICU Medical’s revenue for the quarter was down 8.0% compared to the same quarter last year. ICU Medical has set its FY 2025 guidance at 6.850-7.15 EPS. Equities analysts forecast that ICU Medical, Inc. will post 4.11 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on ICUI shares. Raymond James Financial reduced their target price on shares of ICU Medical from $187.00 to $180.00 and set a “strong-buy” rating on the stock in a report on Friday, August 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of ICU Medical in a report on Wednesday, October 8th. Wall Street Zen upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a report on Friday, September 5th. KeyCorp reduced their price objective on shares of ICU Medical from $191.00 to $173.00 and set an “overweight” rating on the stock in a report on Tuesday. Finally, Piper Sandler raised their price objective on shares of ICU Medical from $145.00 to $153.00 and gave the company an “overweight” rating in a report on Wednesday, September 10th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $176.50.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.